187 related articles for article (PubMed ID: 25724377)
21. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation of miR-212 expression in lung cancer.
Incoronato M; Urso L; Portela A; Laukkanen MO; Soini Y; Quintavalle C; Keller S; Esteller M; Condorelli G
PLoS One; 2011; 6(11):e27722. PubMed ID: 22110741
[TBL] [Abstract][Full Text] [Related]
23. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
24. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Codacci-Pisanelli G; Frati L; Mini E
J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
[No Abstract] [Full Text] [Related]
25. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
26. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer.
Tu Z; Chen X; Tian T; Chen G; Huang M
Aging (Albany NY); 2021 Feb; 13(5):7397-7415. PubMed ID: 33658396
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
[TBL] [Abstract][Full Text] [Related]
29. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ
Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596
[TBL] [Abstract][Full Text] [Related]
30. For EGFR research, new targeted drugs mean new questions.
Vastag B
J Natl Cancer Inst; 2005 May; 97(9):628-30. PubMed ID: 15870431
[No Abstract] [Full Text] [Related]
31. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
33. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
34. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
35. Small molecule inhibitors of EZH2: the emerging translational landscape.
Keilhack H; Smith JJ
Epigenomics; 2015; 7(3):337-41. PubMed ID: 26077423
[No Abstract] [Full Text] [Related]
36. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
37. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
38. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
[TBL] [Abstract][Full Text] [Related]
39. [Advances of medical treatment in advanced non-small cell lung cancer in 2011 American Society of Clinical Oncology Annual Meeting].
Xu X; Wang J
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):943-8. PubMed ID: 22152695
[No Abstract] [Full Text] [Related]
40. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
Verma SK
Methods Mol Biol; 2015; 1238():677-88. PubMed ID: 25421686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]